Materials – European HIV Clinical Forum 2019

 

Tuesday 5 November 2019

 Session 1  - Position of INSTIs in clinical management of PLWH
Chairs: Jonathan Schapiro & Marcel Stöckle
 

First line regimens in different European countries 2019 – an overview
Milosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland

 

 

Second generation INSTI regimens for drug naive patients: State of the Art
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, Cambridge, USA

 

 Abstract
Longitudinal trends in self-reported side effects and prescribed 3rd agent in ART
(No permission to publish slides or video)
Gaetano Marrone, Prof.
Department Of Infectious Disease, Karolinska Hospital, Stockholm
 Session 2  - Treatment and Prevention: State of the Art
Chairs: Anne-Geneviève Marcelin & Saye Khoo
 

When to start antiretroviral therapy after diagnosis – trade-offs and considerations
Anton Pozniak, MD, FRCP
Chelsea and Westminster Hospital, London, UK

 

 Round table on PrEP
 

Update on PrEP use in Europe
Ann Sullivan, MBBS, DIPGUM, DFFP, MD, FRCP
Chelsea and Westminster Hospital, London, UK

 

 

Challenges of long-term PrEP
Pep Coll, MD
AIDS Research Institute-IrsiCaixa, Barcelona, Spain

 

 

Oral versus injectable PrEP
(Video not yet available)
Saye Khoo, MD, PhD
University of Liverpool, Liverpool, UK

 Session 3  - Novel treatment options
Chairs: Anton Pozniak & Laura Waters
 

New treatments and treatment paradigms
Sharon Walmsley, CM, MD, FRCPC
University Health Network, Toronto, Canada

 

 

Long acting parenteral antiretroviral regimens - where might they fit?
Saye Khoo, MD, PhD
University of Liverpool, Liverpool, UK

 

 

Single tablet regimens versus multiple pills – is there a meaningful difference?
Bonaventura Clotet, MD, PhD
Fundació Irsicaixa, Barcelona, Spain

 

 

Abstract
HIV and Ageing - Primary and secondary prevention of coronary artery disease among People living with HIV
(No permission to publish slides or video)

Gaetano Marrone, Prof.
Karolinska Hospital, Stockholm

 Session 4  - Round table on long-term ramifications of expanded global first line second-generation INSTI use
Moderators: Dan Kuritzkes & Bonaventura Clotet
 Round table on long-term ramifications of expanded global first line second-generation INSTI use
 

Impact on transmitted and acquired drug resistance
Anne-Geneviève Marcelin, PharmD, PhD
Hôpital Pitié-Salpétrière, France

 

 

Impact on women’s health & weight gain
Laura Waters, MD
Central & North West London NHS Trust, London, UK

 

 

Impact on children and adolescence
Natella Rakhmanina, MD, PhD
The George Washington University, Children’s National Health System, Washington, US